New synthesis of a late-stage tetracyclic key intermediate of lumateperone
暂无分享,去创建一个
G. Simig | Balázs Volk | T. Nagy | M. Milen | Bálint Nyulasi
[1] James Robert Brašić,et al. The role of lumateperone in the treatment of schizophrenia , 2021, Therapeutic advances in psychopharmacology.
[2] A. Fienberg,et al. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. , 2021, Advances in pharmacology.
[3] J. Rey,et al. Lumateperone: A Novel Antipsychotic for Schizophrenia , 2020, The Annals of pharmacotherapy.
[4] Haibo Mei,et al. Fluorine-containing drugs approved by the FDA in 2019 , 2020 .
[5] Hannah A. Blair. Lumateperone: First Approval , 2020, Drugs.
[6] James Robert Brašić,et al. An evaluation of lumateperone tosylate for the treatment of schizophrenia , 2019, Expert opinion on pharmacotherapy.
[7] Chao Song,et al. Access to the Cinnoline Scaffold via Rhodium-Catalyzed Intermolecular Cyclization under Mild Conditions. , 2016, Organic letters.
[8] G. Snyder,et al. Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. , 2014, Journal of medicinal chemistry.
[9] A. Nishida,et al. Simple Synthesis of Racemic Pyrrolo[2,3-b]indoles: Formal Total Synthesis of (±)-Physostigmine , 2002 .
[10] J. Prost,et al. New triazine derivatives as potent modulators of multidrug resistance. , 1992, Journal of medicinal chemistry.